Janis leads cross-functional activities in regulatory science and international health policy for IFPMA, while partnering with policy experts and stakeholders to strengthen the pharmaceutical regulatory environment.
She is responsible for guiding the organization’s regulatory team to successfully deliver its policy objectives and advocate for improved regulatory system strengthening.
Prior to joining IFPMA,Janis worked in quality assurance and regulatory compliance fora US-based multinational company that specializes in supplying custom value-added food products to a world leading food service and retail food brand.
Janis holds a Master of Science in Communication-Public Relations and a Bachelor of Science in Agriculture-Food Science.
Strong, capable, and efficient regulatory systems are fundamental to improving access to medicines and vaccines. All of us have a responsibility to engage in these conversations, collaborate, and improve the lives and livelihoods of patients globally.
More from Janis
How do we improve clinical trials post-pandemic?
The COVID-19 pandemic has taught us a lot and yet we can still keep learning. While the pandemic has impacted everyone, it has provided a spark for further exploration into how clinical trials should be improved globally.
Read moreCOVID-19 is modernising the way we run clinical trials: what will happen next?
This blog was originally published on Media Planet Clinical Trials Campaign on 20 May 2021. “The biopharmaceutical industry and regulatory authorities have been working to ensure clinical trials have been progressing in all diseases throughout the global pandemic. When the COVID-19 pandemic began, most of our focus went to ‘how can my family and I...
Read more